FDMT vs REGN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

REGN is the larger of the two ($93.98B market cap): the incumbent the market prices for continued execution (12.85x forward earnings, beta 0.09). FDMT is the smaller challenger ($687.24M), priced similarly on forward earnings (-3.04x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

FDMT vs REGN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricFDMTREGNWhat it tells you
Market cap$687.24M$93.98BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-3.0412.85Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta2.910.09Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range55% of range79% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.682.72How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how FDMT and REGN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. FDMT and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined FDMT and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does 4D Molecular Therapeutics (FDMT) do?

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, and known as 4DMT) is an Emeryville, California biotech founded in 2013 that engineers adeno-associated virus (AAV) vectors through a directed-evolution platform the company calls Therapeutic Vector Evolution. Its lead candidate, 4D-150, pairs the proprietary R100 vector with a transgene encoding aflibercept plus an RNA interference approach against VEGF-C, delivered by a single in-office intravitreal injection. The goal is to replace repeated monthly or bimonthly anti-VEGF eye injections with one durable treatment. Two Phase 3 wet AMD trials are fully enrolled: 4FRONT-1 randomized 523 patients with topline data guided to Q2 2027, and 4FRONT-2 finished enrollment in June 2026 with more than 500 patients and topline guided to H2 2027. On September 28, 2026 the company enrolled the first patients in 4SIGHT, a 514-patient Phase 3 in diabetic macular edema comparing 4D-150 with aflibercept 2 mg every eight weeks, with a primary endpoint of non-inferior visual acuity at week 52. Behind the retina franchise sit 4D-175 for geographic atrophy, 4D-710 for cystic fibrosis lung disease, and 4D-725 for alpha-1-antitrypsin deficiency, all of which the company says it is advancing mainly through outside funding rather than its own balance sheet.

Full FDMT guide

What does Regeneron Pharmaceuticals (REGN) do?

Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base. Total revenue then stepped up to about $4.29 billion in Q2 2026, up roughly 17% year over year, taking trailing twelve-month revenue to about $15.5 billion and net income to about $4.3 billion.

Full REGN guide

FDMT vs REGN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • FDMT drivers: Two fully enrolled Phase 3 wet AMD trials; Durability data that defines the commercial pitch.
  • REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Everything concentrates in one molecule and two wet AMD readouts, so a miss or an ambiguous result in 4FRONT-1 or 4FRONT-2 would remove most of the reason to own the shares, and the new DME trial adds cost on the same molecule rather than diversification away from it. For REGN, the clearest risk is Eylea biosimilar erosion.

FDMT or REGN: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick FDMT if you believe its drivers more; REGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the FDMT and REGN guides.

FDMT vs REGN: the full fundamentals

FDMT. Conventional multiples do not apply, because the revenue line is a licensing payment rather than a business. Stripping out the roughly $431 million of cash reported at June 30 and adding back $20 million of drawn Hercules debt leaves an enterprise value near $280 million on the common-share count at the October 16 price, so the market is assigning a few hundred million dollars to a Phase 3 asset in two multi-billion-dollar indications plus four earlier programs. Book value is the only anchor with real content here, at roughly $408 million of stockholders' equity at mid-year against an accumulated deficit of about $858 million. The shares traded between roughly $6.96 and $16.93 over the trailing year, and the average of 11 analyst targets is about $28.

REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron has beaten EPS estimates in each of the last four quarters, most sharply in Q2 2026 (about $14.29 against $10.21), and the shares rose about 18% over three months to roughly $794, up about 40% over a year. Consensus for Q3 2026, due October 30, sits near $16.06 of EPS on about $4.54 billion of revenue, and the ~13x forward P/E reflects the market weighing strong Dupixent growth against Eylea biosimilar erosion expected to accelerate around the fourth quarter of 2026.

Headline figures (approximate, October 2026): FDMT shows revenue (ttm) ~$92M, of which ~$85M was a one-time Otsuka upfront, product revenue $0, no approved products since inception, net loss (ttm / q2 2026) ~$179M / ~$72.9M, eps (q2 2026 vs estimate) ~$(1.04) vs ~$(1.02); REGN shows total revenue (ttm) ~$15.5 billion, q2 2026 total revenue ~$4.29 billion (up ~17% YoY), q2 2026 eps vs estimate ~$14.29 vs ~$10.21, net income (ttm) ~$4.3 billion (~28% net margin).

The bottom line: FDMT vs REGN

FDMT and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined FDMT and REGN exposure against your real portfolio. It is not an investment adviser.

Wondering how FDMT or REGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about 4D Molecular Therapeutics

Ask Walnut's AI anything about FDMT and see how it fits what you own.

FAQ

What is the difference between FDMT and REGN?

+

4D Molecular Therapeutics, Inc. Regeneron makes money primarily through two large franchises. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is FDMT or REGN the better stock?

+

Neither is universally better. REGN is the larger incumbent; FDMT is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, FDMT or REGN?

+

On forward P/E (as of November 2026), FDMT trades at -3.04x and REGN at 12.85x, so FDMT is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both FDMT and REGN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of FDMT vs REGN?

+

FDMT: Everything concentrates in one molecule and two wet AMD readouts, so a miss or an ambiguous result in 4FRONT-1 or 4FRONT-2 would remove most of the reason to own the shares, and the new DME trial adds cost on the same molecule rather than diversification away from it. Intravitreal AAV carries a specific safety history around intraocular inflammation and hypotony that has derailed competing programs, and long-term ocular safety in a several-hundred-patient Phase 3 population is a different test than an open-label Phase 2b. Cash burn ran near $70 million a quarter in the first half of 2026, and while the guided runway into the second half of 2028 covers the readouts, it does not cover a commercial launch, so further equity raises or partnerships are likely; a November 2025 offering and an active at-the-market program show how that has been funded before. Insiders sold shares worth about $0.8 million in September and $0.75 million in October 2026 per SEC filings. The competitive bar is also rising, since Roche's Vabysmo and Regeneron's higher-dose Eylea already stretch dosing intervals and aflibercept biosimilars are compressing the price of the incumbent standard; sector headlines move these stocks together, as when an EyePoint trial setback in August 2026 lifted FDMT and Kodiak and 4DMT updates in late September hit Ocular Therapeutix. Note the share count trap as well: roughly 55.2 million common shares were outstanding on August 10, 2026, alongside 16.9 million pre-funded warrants exercisable at $0.0001, so per-share and market-cap figures vary by source. On the positive side of the disclosure ledger, the Q2 2026 10-Q stated there were no material legal proceedings outstanding at June 30, 2026, and the company reported no going-concern qualification. REGN: The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell FDMT or REGN; figures are approximate and dated (as of November 2026). Verify current data before investing.